Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-acute Lymphoblastic Leukemia Patients.

NCT00724360 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT00724360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00724360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-acute Lymphoblastic Leukemia Patients.
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2006
Completion date
November 30, 2011
Enrollment
15 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory leukemia